ArticleInternational journal of clinical pharmacy2025

Post-marketing safety of pralsetinib: a real-world disproportionality analysis based on the FDA adverse event reporting system database.

Zheng Shi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.